Karin Blumer
Head Communication and Patient Relations Cell and Gene Therapy, Oncology Region Europe, Novartis Karin Blumer is Head of Communications and Patient Relations Europe for Cell and Gene Therapies at Novartis Oncology. She oversees external and internal communications as well as patient relations of this portfolio – which includes the first ever approved cell-based gene therapy for two distinct blood cancers - across Europe, Israel and Russia. Karin has been with Novartis since 2001. She joined the Pharma Division in a policy and public affairs role, overseeing orphan drug and R&D policy issues. Subsequently she held a variety of global and …
Head Communication and Patient Relations
Cell and Gene Therapy, Oncology Region Europe, Novartis
Karin Blumer is Head of Communications and Patient Relations Europe for Cell and Gene Therapies at Novartis Oncology. She oversees external and internal communications as well as patient relations of this portfolio – which includes the first ever approved cell-based gene therapy for two distinct blood cancers - across Europe, Israel and Russia.
Karin has been with Novartis since 2001. She joined the Pharma Division in a policy and public affairs role, overseeing orphan drug and R&D policy issues. Subsequently she held a variety of global and local public affairs, policy and communication positions at Group level.
Prior to joining Novartis, Karin worked as a freelance science journalist and policy advisor.
Karin is a state board approved veterinarian (Ludwig-Maximilians-University Munich) and completed philosophy studies at the Jesuit Faculty for Philosophy/Munich. She authored two interdisciplinary PhDs on the ethics of animal research and the philosophical aspects of risk assessment.
Karin is a German citizen who lives in the Swiss Basel area with her teenage daughter.
See more
Cell and Gene Therapy, Oncology Region Europe, Novartis
Karin Blumer is Head of Communications and Patient Relations Europe for Cell and Gene Therapies at Novartis Oncology. She oversees external and internal communications as well as patient relations of this portfolio – which includes the first ever approved cell-based gene therapy for two distinct blood cancers - across Europe, Israel and Russia.
Karin has been with Novartis since 2001. She joined the Pharma Division in a policy and public affairs role, overseeing orphan drug and R&D policy issues. Subsequently she held a variety of global and local public affairs, policy and communication positions at Group level.
Prior to joining Novartis, Karin worked as a freelance science journalist and policy advisor.
Karin is a state board approved veterinarian (Ludwig-Maximilians-University Munich) and completed philosophy studies at the Jesuit Faculty for Philosophy/Munich. She authored two interdisciplinary PhDs on the ethics of animal research and the philosophical aspects of risk assessment.
Karin is a German citizen who lives in the Swiss Basel area with her teenage daughter.
Articles: Karin Blumer
Cell & Gene Therapy: Command? Consent? Collaborate!
Opinion / Novartis Oncology’s Emanuele Ostuni (lead author) and Karin Blumer draw on their experience commercialising CAR-T therapies to make the case for the myriad benefits of collaborative, as opposed to command, leadership, the impact of company and team culture on the innovation journey, and why we must not confuse collaboration with consensus. In a recent…
Latest Report
